Recurrence of Hepatocellular Carcinoma in Patients with Low Albumin-Bilirubin Grade in TACE Combined with Ablation: A Random Forest Cox Predictive Model

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–1362. doi:10.1016/s0140-6736(22)01200-4
   PubMed Web of Science ®Google Scholar
• Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(5):584–590. doi:10.1097/cm9.0000000000002108
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Bai XM, Cui M, Yang W, et al. The 10-year survival analysis of radiofrequency ablation for solitary hepatocellular carcinoma 5 cm or smaller: primary versus recurrent HCC. Radiology. 2021;300(2):458–469. doi:10.1148/radiol.2021200153
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Lin PT, Teng W, Jeng WJ, et al. Dynamic change of albumin-bilirubin score is good predictive parameter for prognosis in chronic hepatitis C-hepatocellular carcinoma patients receiving transarterial chemoembolization. Diagnostics. 2022;12(3):1.
   Web of Science ®Google Scholar
• Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–50. doi:10.1053/j.gastro.2004.09.014
   PubMed Web of Science ®Google Scholar
• Su K, Shen Q, Tong J, et al. Construction and validation of a nomogram for HBV-related hepatocellular carcinoma: a large, multicenter study. Ann Hepatol. 2023;28(4):101109. doi:10.1016/j.aohep.2023.101109
   PubMed Web of Science ®Google Scholar
• Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis. 2008;28(1):110–122. doi:10.1055/s-2008-1040325
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi:10.1200/jco.2014.57.9151
   PubMed Web of Science ®Google Scholar
• Kuo YH, Wang JH, Hung CH, et al. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. J Gastroenterol Hepatol. 2017;32(12):1975–1981. doi:10.1111/jgh.13783
   PubMed Web of Science ®Google Scholar
• Wang YY, Zhong JH, Su ZY, et al. Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. Br J Surg. 2016;103(6):725–734. doi:10.1002/bjs.10095
   PubMed Web of Science ®Google Scholar
• Gui B, Weiner AA, Nosher J, et al. Assessment of the Albumin-Bilirubin (ALBI) grade as a prognostic indicator for hepatocellular carcinoma patients treated with radioembolization. Am J Clin Oncol. 2018;41(9):861–866. doi:10.1097/coc.0000000000000384
   PubMed Web of Science ®Google Scholar
• Mishra G, Majeed A, Dev A, et al. Clinical utility of albumin bilirubin grade as a prognostic marker in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a systematic review and meta-analysis. J Gastrointest Cancer. 2023;54(2):420–432. doi:10.1007/s12029-022-00832-0
   PubMed Web of Science ®Google Scholar
• Bannaga A, Arasaradnam RP. Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: a systematic review. World J Gastroenterol. 2020;26(33):5022–5049. doi:10.3748/wjg.v26.i33.5022
   PubMed Web of Science ®Google Scholar
• Demirtas CO, D’Alessio A, Rimassa L, Sharma R, Pinato DJ. ALBI grade: evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep. 2021;3(5):100347. doi:10.1016/j.jhepr.2021.100347
   PubMedGoogle Scholar
• Toyoda H, Johnson PJ. The ALBI score: from liver function in patients with HCC to a general measure of liver function. JHEP Rep. 2022;4(10):100557. doi:10.1016/j.jhepr.2022.100557
   PubMedGoogle Scholar
• Long H, Xie X, Huang G, Huang T, Xie X, Liu B. Prognostic role of albumin-bilirubin grade in hepatocellular carcinoma after ultrasound-guided percutaneous radiofrequency ablation: a single-center experience over a decade. Surg Laparosc Endosc Percutan Tech. 2022;32(3):350–356. doi:10.1097/sle.0000000000001049
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun. 2021;41(10):1037–1048. doi:10.1002/cac2.12197
   PubMed Web of Science ®Google Scholar
• Schmucker DL. Aging and the liver: an update. J Gerontol a Biol Sci Med Sci. 1998;53(5):B315–20. doi:10.1093/gerona/53a.5.b315
   PubMed Web of Science ®Google Scholar
• Wang Q, Qiao W, Zhang H, et al. Nomogram established on account of Lasso-Cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma. Front Immunol. 2022;13:1019638. doi:10.3389/fimmu.2022.1019638
   PubMed Web of Science ®Google Scholar
• Ho MC, Hasegawa K, Chen XP, et al. Surgery for intermediate and advanced hepatocellular carcinoma: a consensus report from the 5th Asia-pacific primary liver cancer expert meeting (APPLE 2014). Liver Cancer. 2016;5(4):245–256. doi:10.1159/000449336
   PubMed Web of Science ®Google Scholar
• Qiao W, Fan Z, Wang Q, Jin R, Hu C. Development and Validation of a Nomogram to Predict the Recurrence of HCC Patients Undergoing CECT After Ablation. J Hepatocell Carcinoma. 2024;11:65–79. doi:10.2147/jhc.S441540
   PubMed Web of Science ®Google Scholar
• Wang Q, Qiao W, Liu B, et al. The monocyte to lymphocyte ratio not only at baseline but also at relapse predicts poor outcomes in patients with hepatocellular carcinoma receiving locoregional therapy. BMC Gastroenterol. 2022;22(1):98. doi:10.1186/s12876-022-02180-6
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zhu Y, Ni X, et al. Serum GGT/ALT ratio predicts vascular invasion in HBV-related HCC. Cancer Cell Int. 2021;21(1):517. doi:10.1186/s12935-021-02214-1
   PubMed Web of Science ®Google Scholar
• Li S, Xu W, Liao M, et al. The significance of gamma-glutamyl transpeptidase to lymphocyte count ratio in the early postoperative recurrence monitoring and prognosis prediction of AFP-negative hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:23–33. doi:10.2147/jhc.S286213
   PubMed Web of Science ®Google Scholar
• Zhao H, Liu X, Xu R, Guo X, Shen A. Predictive value of and relationship between the gamma-glutamyl transpeptidase to lymphocyte ratio and CT features in hepatocellular carcinoma patients with postoperative adjuvant TACE. J buon. 2021;26(4):1346–1354.
   PubMedGoogle Scholar
• Zhang W, Bi Y, Yang K, et al. A new model based on gamma-glutamyl transpeptidase to lymphocyte ratio and systemic immune-inflammation index can effectively predict the recurrence of hepatocellular carcinoma after liver transplantation. Front Oncol. 2023;13:1178123. doi:10.3389/fonc.2023.1178123
   PubMed Web of Science ®Google Scholar
• Haruki K, Shiba H, Saito N, et al. Risk stratification using a novel liver functional reserve score of combination prothrombin time-international normalized ratio to albumin ratio and albumin in patients with hepatocellular carcinoma. Surgery. 2018;164(3):404–410. doi:10.1016/j.surg.2018.02.022
   PubMed Web of Science ®Google Scholar
• Deng Y, Pang Q, Miao RC, et al. Prognostic significance of pretreatment albumin/globulin ratio in patients with hepatocellular carcinoma. Onco Targets Ther. 2016;9:5317–5328. doi:10.2147/ott.S109736
   PubMed Web of Science ®Google Scholar
• Wang S, Deng Y, Yu X, et al. Prognostic significance of preoperative systemic inflammatory biomarkers in patients with hepatocellular carcinoma after microwave ablation and establishment of a nomogram. Sci Rep. 2021;11(1):13814. doi:10.1038/s41598-021-93289-3
   PubMed Web of Science ®Google Scholar
• Li J, Li Z, Hao S, et al. Inversed albumin-to-globulin ratio and underlying liver disease severity as a prognostic factor for survival in hepatocellular carcinoma patients undergoing transarterial chemoembolization. Diagn Interv Radiol. 2023;29(3):520–528. doi:10.5152/dir.2022.211166
   PubMed Web of Science ®Google Scholar
• Zhao S, Wang M, Yang Z, et al. Comparison between child-Pugh score and albumin-bilirubin grade in the prognosis of patients with HCC after liver resection using time-dependent ROC. Ann Transl Med. 2020;8(8):539. doi:10.21037/atm.2020.02.85
   PubMed Web of Science ®Google Scholar
• Xu W, Li R, Liu F. Novel prognostic nomograms for predicting early and late recurrence of hepatocellular carcinoma after curative hepatectomy. Cancer Manag Res. 2020;12:1693–1712. doi:10.2147/cmar.S241959
   PubMed Web of Science ®Google Scholar
• Chen PC, Chiu NC, Su CW, et al. Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy. J Chin Med Assoc. 2019;82(1):2–10. doi:10.1097/jcma.0000000000000001
   PubMed Web of Science ®Google Scholar
• Ni JY, Fang ZT, Sun HL, et al. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation. Eur Radiol. 2020;30(4):2377–2390. doi:10.1007/s00330-019-06438-8
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhao L, Zhou Y, Ding J, Zhang Q, Jing X. The comparison between albumin-bilirubin grade and Child-Pugh grade for assessing the prognosis of hepatocellular carcinoma after thermal ablation: a propensity score-matched analysis. Transl Cancer Res. 2022;11(8):2523–2535. doi:10.21037/tcr-22-244
   PubMed Web of Science ®Google Scholar
• Carr BI, Guerra V. Serum albumin levels in relation to tumor parameters in hepatocellular carcinoma patients. Int J Biol Markers. 2017;32(4):e391–e396. doi:10.5301/ijbm.5000300
   PubMed Web of Science ®Google Scholar
• Bağırsakçı E, Şahin E, Atabey N, Erdal E, Guerra V, Carr BI. Role of albumin in growth inhibition in hepatocellular carcinoma. Oncology. 2017;93(2):136–142. doi:10.1159/000471807
   PubMed Web of Science ®Google Scholar
• Peng ZW, Zhang YJ, Liang HH, Lin XJ, Guo RP, Chen MS. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology. 2012;262(2):689–700. doi:10.1148/radiol.11110637
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Chen MS, Chen Y, Lau WY, Peng Z. Long-term outcomes of transcatheter arterial chemoembolization combined with radiofrequency ablation as an initial treatment for early-stage hepatocellular carcinoma. JAMA Network Open. 2021;4(9):e2126992. doi:10.1001/jamanetworkopen.2021.26992
   PubMed Web of Science ®Google Scholar
• Endo K, Kuroda H, Oikawa T, et al. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma. Scand J Gastroenterol. 2018;53(12):1575–1583. doi:10.1080/00365521.2018.1548645
   PubMed Web of Science ®Google Scholar